How to Schema

How to Apply for the Bio Medica Laboratories IPO: Step-by-Step Investment Guide

Summary:
 

Bio Medica Laboratories Ltd is a pharmaceutical manufacturing company engaged in producing injectable formulations for human and veterinary healthcare applications. The Bio Medica Laboratories IPO will open for subscription on May 21, 2026, and close on May 25, 2026. The IPO consists of 37,72,000 shares with a price band of ₹132 to ₹139 per share and is proposed to be listed on the SME platform of NSE. The company plans to utilise the issue proceeds for loan repayment, setting up a new manufacturing facility at the existing premises, and general corporate purposes. Investors can apply for the IPO through the ASBA process using net banking or UPI-supported trading platforms before the issue closing date.

Bio Medica Laboratories Ltd is engaged in the manufacturing of pharmaceutical parenteral formulations, with a focus on injectable medicines used in human and veterinary healthcare. The company manufactures liquid injections and dry powder injections in single-dose and multi-dose formats. Its product portfolio includes generic medicines, branded formulations, and over-the-counter (OTC) products. Operating through a business-to-business (B2B) contract manufacturing model, the company develops formulations according to client-specific requirements and packaging specifications. The company also holds Good Manufacturing Practices (GMP) certification issued by the Food & Drugs Administration, Madhya Pradesh. The company operates two manufacturing facilities in Indore, Madhya Pradesh, and supplies products for pharmaceutical companies under contractual arrangements. Its operations are linked to the pharmaceutical manufacturing segment, particularly injectable formulations used across different healthcare applications.

Investors planning to apply for the Bio Medica Laboratories Ltd IPO can do so through the ASBA (Application Supported by Blocked Amount) process available via net banking or through UPI-enabled trading applications. Applicants are required to log in to their trading or banking platform, select the IPO section, choose Bio Medica Laboratories Ltd IPO, enter the bid quantity and price within the stated price band, and approve the UPI mandate or ASBA request before the issue closing date.

For more details, visit the Bio Medica Laboratories IPO page.

Bio Medica Laboratories IPO Details and Objectives

Details

Information

IPO Date

May 21, 2026 to May 25, 2026

Issue Size

37,72,000 shares (agg. up to ₹52.43 Cr)

Price Band

₹132 to ₹139 per share

Lot Size

1,000 shares

Listing At

SME, NSE 

Market Maker

Prabhat Financial Services Ltd. 

Purpose of the IPO

  • Repayment of loan

  • Enhancement of the company’s existing production capabilities by setting up of new manufacturing facility at the existing premises

  • General corporate purposes 

Timeline of Bio Medica Laboratories IPO

Event

Date

IPO Open Date

Thu, May 21, 2026

IPO Close Date

Mon, May 25, 2026

Tentative Allotment

Tue, May 26, 2026

Initiation of Refunds

Wed, May 27, 2026

Credit of Shares to Demat

Wed, May 27, 2026

Tentative Listing Date

Fri, May 29, 2026

Cut-off time for UPI mandate confirmation

5 PM on Mon, May 25, 2026  

Pricing & Lot Size of Bio Medica Laboratories IPO

Price Band for the IPO

  • ₹132 to ₹139 per share

Minimum Lot Size and Application Details

Application

Lots

Shares

Amount

Individual investors (Retail) (Min)

2

2,000

₹2,78,000

Individual investors (Retail) (Max)

2

2,000

₹2,78,000

S-HNI (Min)

3

3,000

₹4,17,000

S-HNI (Max)

7

7,000

₹9,73,000

B-HNI (Min)

8

8,000

₹11,12,000

Bio Medica Laboratories IPO Application Process

The Bio Medica Laboratories IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:

Step 1: Login to Your Trading Platform

Access your trading account using the trading platform.

Step 2: Navigate to the IPO Section

Go to the IPO section to view active IPO listings.

Step 3: Select the Open IPO and Click Apply

Locate Bio Medica Laboratories IPO in the list of available IPOs and click the ‘Apply’ button.

Step 4: Enter the Quantity of Shares You Wish to Apply For

Specify the number of shares (lot size: 1000 shares) within the price band of ₹132 to ₹139 per share.

Step 5: Provide Your UPI ID

Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.

Step 6: Confirm the Application

Review your application details and confirm the UPI mandate before 5 PM on the last application day.

Step 7: Complete the Process and Wait for IPO Allotment Status

Submit the application and monitor the allotment status to check if shares have been allocated to you.

Shares Offered in Bio Medica Laboratories IPO

The allocation of shares in the Bio Medica Laboratories IPO is structured across investor categories in line with applicable regulatory requirements. The issue provides defined reservations for qualified institutional buyers, non-institutional investors, and retail individual investors, with each category allotted a specified proportion of the net issue. This allocation framework outlines how the shares offered are distributed among different classes of investors.

Investor Category

Shares Offered

% of Net Issue

% of Total Issue

QIB Shares Offered

36,000

1.00%

0.95%

NII (HNI) Shares Offered

17,55,000

48.98%

46.53%

  − bNII > ₹10L

11,70,000

-

31.02%

  − sNII < ₹10L

5,85,000

-

15.51%

Retail Shares Offered

17,92,000

50.01%

47.51%

Firm Reservations

Market Maker Shares Offered

1,89,000

-

5.01%

Total Shares Offered

37,72,000

100.00%

100.00%

This reservation structure reflects the categorisation and allocation approach disclosed for the issue, indicating the proportion of shares available to each investor segment.

Financial Health and Performance

Key Financial Metrics

  • Total Assets: Grew from ₹17.57 crore in FY23 to ₹39.12 crore as of March 2025.

  • Total Income: Recorded at ₹38.33 crore in March 2025, as compared to ₹16.25 crore in FY23.

  • Profit After Tax (PAT): Reported at ₹9.79 crore in March 2025, and ₹0.33 crore in FY23.

  • Net Worth: Recorded at ₹14.73 crore in March 2025 compared to ₹2.44 crore in FY23.

  • Reserves & Surplus: Stood at ₹5.55 crore in March 2025, as compared to ₹2.34 crore in FY23.

  • Total Borrowings: Stood at ₹15.01 crore in March 2025, as compared to ₹9.61 crore in FY23.

  • EBITDA: Stood at ₹15.21 crore in March 2025 in comparison to ₹1.70 crore in FY23.

Recent Performance and Growth Prospects

  • The company reported growth in its asset base during the reported financial period, reflecting an expansion in operational scale and business activities.

  • Income levels showed an upward trend over the period under review, indicating increased business operations and higher revenue generation from core activities.

  • Profitability improved during the reported period, supported by growth in business performance and operational execution.

  • The company’s net worth strengthened over time, reflecting changes in retained earnings and overall financial position.

  • Reserves and surplus recorded growth during the period, indicating an increase in accumulated earnings within the business.

  • Borrowings also increased during the reported financial years, reflecting the company’s financing requirements for operational and business-related activities.

  • Operating performance, as reflected through EBITDA, showed improvement over the review period, indicating changes in earnings generated from core business operations before finance costs, taxes, depreciation, and amortisation.

  • The company’s financial performance reflects expansion in operations alongside developments in profitability and operational capacity during the stated period.

Investment Risks and Opportunities

Potential Risks of Investing in the IPO

  • The company operates through a contract manufacturing business model, which may result in dependence on client-specific orders, agreements, and continuation of business relationships with pharmaceutical companies.

  • The pharmaceutical manufacturing industry is subject to regulatory approvals, quality standards, and compliance requirements. Any changes in regulations, certifications, or operational compliance may affect business operations and manufacturing activities.

Opportunities and Growth Potential

  • The proposed utilisation of IPO proceeds towards setting up a new manufacturing facility may support expansion in production capabilities and operational capacity over time.

  • The company operates in the pharmaceutical injectable segment and manufactures products catering to both human and veterinary healthcare requirements, which provides exposure to multiple healthcare-related applications and business segments.

Key Performance Indicator (KPI)

KPI

Nov 30, 2025

Mar 31, 2025

ROE

54.41%

99.59%

ROCE

23.22%

48.20%

Debt/Equity

2.23

1.02

RoNW

54.41%

99.59%

PAT Margin

30.35%

25.64%

EBITDA Margin

47.11%

39.83%

Price to Book Value

-

8.66

Bio Medica Laboratories IPO Registrar & Lead Managers

Registrar

Lead Manager(s)

Skyline Financial Services Pvt. Ltd.

Narnolia Financial Services Ltd.

Company Address of Bio Medica Laboratories Ltd

Plot No. 11B-11C,

Sector-E, Sanwer Road

Industrial Area, Industrial Estate (Indore),

Indore, Madhya Pradesh, 452015

Phone: +91 7314102751

Email: companysecretary@biomedica.co.in

Website: https://biomedica.co.in/

Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Bio Medica Laboratories IPO allotment status.

Frequently Asked Questions

Published Date : 21 May 2026

Disclaimer :

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

QR code to download Bajaj Broking App

9 lakh+ Users

icon-with-text

4.9 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,300 Cr+ MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|